Stevanato Group (STVN) Competitors

Zimmer Biomet (NYSE:ZBH) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, community ranking, earnings, profitability, valuation and analyst recommendations.

Which has more volatility & risk, ZBH or STVN?

Zimmer Biomet has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.

Do analysts prefer ZBH or STVN?

Zimmer Biomet presently has a consensus price target of $124.15, indicating a potential upside of 21.91%. Given Zimmer Biomet's higher probable upside, analysts plainly believe Zimmer Biomet is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.32
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Is ZBH or STVN a better dividend stock?

Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 0.9%. Stevanato Group pays an annual dividend of €0.06 per share and has a dividend yield of 0.3%. Zimmer Biomet pays out 21.6% of its earnings in the form of a dividend. Stevanato Group pays out 12.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Does the media refer more to ZBH or STVN?

In the previous week, Zimmer Biomet had 16 more articles in the media than Stevanato Group. MarketBeat recorded 22 mentions for Zimmer Biomet and 6 mentions for Stevanato Group. Zimmer Biomet's average media sentiment score of 1.41 beat Stevanato Group's score of 1.22 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	17 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stevanato Group	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable earnings and valuation, ZBH or STVN?

Zimmer Biomet has higher revenue and earnings than Stevanato Group. Zimmer Biomet is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$7.68B	2.64	$903.70M	$4.45	22.89
Stevanato Group	$1.10B	6.12	$157.62M	$0.48	46.50

Do insiders & institutionals hold more shares of ZBH or STVN?

88.9% of Zimmer Biomet shares are held by institutional investors. 1.0% of Zimmer Biomet shares are held by company insiders. Comparatively, 0.7% of Stevanato Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Is ZBH or STVN more profitable?

Zimmer Biomet has a net margin of 11.77% compared to Stevanato Group's net margin of 10.47%. Zimmer Biomet's return on equity of 12.99% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	11.77%	12.99%	7.58%
Stevanato Group	10.47%	9.86%	5.79%

Does the MarketBeat Community believe in ZBH or STVN?

Zimmer Biomet received 874 more outperform votes than Stevanato Group when rated by MarketBeat users. Likewise, 67.06% of users gave Zimmer Biomet an outperform vote while only 62.50% of users gave Stevanato Group an outperform vote.

Company	Underperform	Outperform
Zimmer Biomet	Outperform Votes 904 67.06%	Underperform Votes 444 32.94%
Stevanato Group	Outperform Votes 30 62.50%	Underperform Votes 18 37.50%

Summary

Zimmer Biomet beats Stevanato Group on 16 of the 20 factors compared between the two stocks.